6/27/2025

The collaboration comes after Novo Nordisk terminated a frosty Hims & Hers partnership earlier this week.

Source: Yahoo

6/27/2025

With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed.

Source: Yahoo

6/27/2025

The stock's market-beating momentum has come crashing to a halt, following shocking allegations from one of the world's largest pharmaceutical companies.

Source: Yahoo

6/27/2025

STORY: Novo Nordisk is to collaborate with WeightWatchers to sell its blockbuster weight-loss drug Wegovy.Under the deal to start on July 1st, cash-paying patients can access a month's supply of Wegovy through the Danish drugmaker's Novocare pharmacy for $299.Novo recently announced the end of its collaboration with Hims and Hers Health.It cited the telehealth platform's sales of Wegovy copies and marketing tactics.WeightWatchers, which has exited  bankruptcy, says it no longer offers compounded versions of semaglutide.That's the active ingredient in Wegovy.Novo said it is maintaining deals with WeightWatchers rivals Ro and LifeMD.WeightWatchers, intending to shed over $1 billion in debt, filed for Chapter 11 bankruptcy relief in May as part of a restructuring plan.In court documents, the company said its weight management program faced competition from sales of drugs like Wegovy.Demand for cheaper compounded versions of popular weight-loss drugs have risen over the past two years.After its deal with Novo fell apart, Hims' CEO in a statement this week accused the drugmaker of attempting to steer patients toward the branded version of Wegovy.

Source: Yahoo

6/26/2025

Health care stocks edged up late Thursday afternoon, with the NYSE Health Care Index rising 0.2% and

Source: Yahoo

6/26/2025

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 12.1% in the afternoon session after the company's CEO stated that it will continue to offer cheaper, compounded versions of GLP-1 weight-loss drugs. This statement comes on the heels of Novo Nordisk's recent termination of its partnership with Hims & Hers, where it was to supply its branded weight-loss drug, Wegovy. Novo Nordisk ended the collaboration citing concerns over Hims & Hers' promotion and sale of compounded drugs.

Source: Yahoo

6/26/2025

Inside the pharma partnership gone sour

Source: Yahoo

6/26/2025

Hims & Hers Health (NYSE:HIMS) has experienced a tumultuous quarter, marked by Novo Nordisk's termination of their collaboration after allegations of unsafe practices, resulting in a 35% drop in the company's share price. This partnership termination, alongside a class action lawsuit alleging misleading statements about safety and operational risks, contributed to heightened market volatility. Despite a remarkable quarterly earnings report with substantial sales and net income growth, these...

Source: Yahoo

6/26/2025

John Hyland outlines some of the top stories on the trading day on this rendition of Yahoo Finance's Market Minute. Micron (MU) shares fall despite reporting earnings results that beat estimates. Tesla (TSLA) executive Omead Afshar has left the company, according to Bloomberg, with Forbes reporting Afshar was fired. Novo Nordisk (NVO) announces a weight loss drug partnership with Weight Watchers, just after the pharma giant cut ties with Hims & Hers (HIMS). Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute

Source: Yahoo

6/26/2025

The pharmaceutical giant said WeightWatchers will work with CenterWell Pharmacy to fulfill and deliver Wegovy prescriptions.

Source: Yahoo

6/26/2025

Brad Smith outlines some of the top stories on Wall Street in just 60 seconds as part of today's Market Minute. Micron (MU) stock slides, erasing initial gains following the company's earnings results that beat expectations. Meta (META) is reportedly poaching top artificial intelligence (AI) talent from the likes of OpenAI (OPAI.PVT) and Alphabet (GOOG, GOOGL), according to reports from The Wall Street Journal. Novo Nordisk (NVO) announces a weight loss drug partnership with Weight Watchers, just after the pharma giant cut ties with Hims & Hers (HIMS). Stay up to date on the latest market action, minute-by-minute, with Yahoo Finance's Market Minute.

Source: Yahoo

6/26/2025

(Reuters) -Novo Nordisk said on Thursday it will collaborate with WeightWatchers to sell its blockbuster weight-loss drug, Wegovy, starting July 1. The one-time price will also be available through Novo's other telehealth partners through July 31, the company said in a release. Novo recently announced the end of its collaboration with Hims and Hers Health, citing the telehealth platform's sales of Wegovy copies and marketing tactics.

Source: Yahoo

6/26/2025

Viking begins phase III VANQUISH program for VK2735, targeting weight loss in obese adults with or without type II diabetes.

Source: Yahoo

6/26/2025

Eli Lilly bets on next-generation obesity candidates like orforglipron and retatrutide to sustain growth amid rising competition.

Source: Yahoo

6/26/2025

Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a study into a side effect of the jabs.

Source: Yahoo

6/26/2025

The London Biotechnology Show 2025, held from 18 to 19 June, encompassed a range of sessions on automation, regulation, and innovation, amongst others.

Source: Yahoo

6/26/2025

Source: SeekingAlpha

6/26/2025

(Updates with response from Novo Nordisk in the fifth and sixth paragraphs and latest share price mo

Source: Yahoo

6/26/2025

HYDERABAD (Reuters) -Eli Lilly said on Thursday that India's drug regulator had approved the launch of pre-filled injector pens of its blockbuster weight-loss drug, Mounjaro, giving it more options to compete with Novo Nordisk's recently launched Wegovy. Lilly started selling Mounjaro in India in late March for diabetes and obesity, and it was so far available only in 2.5 mg and 5 mg vials. "With this approval, all six dosage options for Mounjaro will soon be available in India, supporting a more personalized approach to treatment," Lilly India President Winselow Tucker said.

Source: Yahoo

6/25/2025

We came across a bullish thesis on Novo Nordisk A/S on Kontra Investments’ Substack by Kontra. In this article, we will summarize the bull’s thesis on NVO. Novo Nordisk A/S’s share was trading at $70.73 as of June 24th. NVO’s trailing and forward P/E were 19.24 and 17.09, respectively, according to Yahoo Finance. Novo Nordisk continues to […]

Source: Yahoo